Loading...
Fueling an Epidemic: Inside the Insys Strategy for Boosting Fentanyl Sales
Senate Committee on Homeland Security and Governmental Affairs
Senate Committee on Homeland Security and Governmental Affairs
Abstract
The Senate Committee on Homeland Security and Governmental Affairs, on behalf of Ranking Member Claire McCaskill, issued a Minority Staff report discussing how the interplay between compensation, for physicians and their sales representatives, drove massive growth for Insys Therapeutics Inc., as it established sales and marketing practices to boost Subsys (Fentanyl) sales. The report published its findings as a warning to policymakers seeking to prevent actors in the pharmaceutical industry from driving the next public health crisis. The report found that Insys executives emphasized the importance of “owning” a physician, through promises of compensation for both sides, which has significantly affected patient treatment. The report concluded that Insys fostered a scheme to profit by utilizing bribes and fraud to contribute to the illicit distribution of Subsys.
Date
2018-10-17
Document Type
Senate Minority Staff Report
Serial Number
Document Length
193 pages
Congress
115
Relation
DOI
Keywords
Staff Reports
PAP Major Code
3: Health
PAP Minor Code
342: Substance, Alcohol and Drug Abuse, Treatment and Education
Related Hearings
N/A